Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 16;11(2):105-116.
doi: 10.1002/cdt3.155. eCollection 2025 Jun.

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Nandhini Jayaprakash  1 , Karthikeyan Elumalai  2
Affiliations
Review

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Nandhini Jayaprakash et al. Chronic Dis Transl Med. .

Abstract

Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N-methyl D-aspartate (NMDA) receptor antagonists, do not reverse or slow the disease course but only treat its manifestations. This limitation has brought attention to the need for treatments that modify the amyloid-beta (Aβ) and tau pathology of the disease. One recent advancement in AD treatment is donanemab, a monoclonal antibody intended to clear Aβ plaques in the brain. It targets pyroglutamyl(3)-Aβ protein (3-42) to remove Aβ deposits and alter the disease course. This review explores the timeline of donanemab use from discovery to clinical use. The pharmacodynamics and pharmacokinetics of the drug are discussed along with typical and suboptimal preclinical and clinical trial results in terms of efficacy, safety, and tolerability. Thus, donanemab is more effective than donepezil and rivastigmine in removing plaques and improving cognition. At the same time, it is not devoid of safety concerns that are typical of the majority of amyloid-targeted medicines. The control to end the treatment after plaque cleaning is a unique selling point for some patients, making it more attractive. The innovation and development of donanemab from research to clinical practice are a clear representation of the role of the field of translational medicine in the practical application of new knowledge in the treatment of AD.

Keywords: Alzheimer's disease; amyloid‐β plaques; clinical trials; donanemab; immunotherapy; neurodegenerative disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

None
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia.
Figure 1
Figure 1
Mechanism of action of donanemab.
Figure 2
Figure 2
Road map of donanemab.
Figure 3
Figure 3
Mechanism of action of donanemab and lecanemab.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Pei J., Palanisamy C. P., Natarajan P. M., et al., “Curcumin‐Loaded Polymeric Nanomaterials as a Novel Therapeutic Strategy for Alzheimer's Disease: A Comprehensive Review,” Ageing Research Reviews 99 (2024): 102393, 10.1016/j.arr.2024.102393. - DOI - PubMed
    1. Pei J., Palanisamy C. P., Jayaraman S., et al., “Proteomics Profiling of Extracellular Vesicle for Identification of Potential Biomarkers in Alzheimer's Disease: A Comprehensive Review,” Ageing Research Reviews 99 (2024): 102359, 10.1016/j.arr.2024.102359. - DOI - PubMed
    1. Alzheimer Association , “Alzheimer's Association 2024 Alzheimer's Disease Facts and Figures,” Alzheimer's Association 20, no. 5 (2024), https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. - PMC - PubMed
    1. Ansari M. A., Tripathi T., Venkidasamy B., et al., “Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers,” Molecular Neurobiology 61, no. 5 (2024): 3042–3089, 10.1007/s12035-023-03730-z. - DOI - PubMed
    1. Jin W., Pei J., Roy J. R., et al., “Comprehensive Review on Single‐Cell RNA Sequencing: A New Frontier in Alzheimer's Disease Research,” Ageing Research Reviews 100 (2024): 102454, 10.1016/j.arr.2024.102454. - DOI - PubMed

LinkOut - more resources